The evolution and clinical impact of hepatitis B virus genome diversity.

Peter A Revill, Thomas Tu, Hans J Netter, Lilly K W Yuen, Stephen A Locarnini, Margaret Littlejohn

Nature reviews. Gastroenterology & hepatology 2020 Oct

filter terms:

b virus (9)

genotypes (1)

humans (1)

reptiles (1)

therapies (2)

Sizes of these terms reflect their relevance to your search.

The global burden of hepatitis B virus (HBV) is enormous, with 257 million persons chronically infected, resulting in more than 880,000 deaths per year worldwide. HBV exists as nine different genotypes, which differ in disease progression, natural history and response to therapy. HBV is an ancient virus, with the latest reports greatly expanding the host range of the Hepadnaviridae (to include fish and reptiles) and casting new light on the origins and evolution of this viral family. Although there is an effective preventive vaccine, there is no cure for chronic hepatitis B, largely owing to the persistence of a viral minichromosome that is not targeted by current therapies. HBV persistence is also facilitated through aberrant host immune responses, possibly due to the diverse intra-host viral populations that can respond to host-mounted and therapeutic selection pressures. This Review summarizes current knowledge on the influence of HBV diversity on disease progression and treatment response and the potential effect on new HBV therapies in the pipeline. The mechanisms by which HBV diversity can occur both within the individual host and at a population level are also discussed.

Citation

Peter A Revill, Thomas Tu, Hans J Netter, Lilly K W Yuen, Stephen A Locarnini, Margaret Littlejohn. The evolution and clinical impact of hepatitis B virus genome diversity. Nature reviews. Gastroenterology & hepatology. 2020 Oct;17(10):618-634